US Breast Cancer Drug Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Around the corners of world, cancer has infused itself in every country, region and each habitable land present over earth. Cancer has become one of those nightmares which haunt every individual once in a life time this is because of the increasing incidence rates and no proper care available until now. Given the steady increase in global cancer incidence with its associated morbidity and mortality, together with the spiraling healthcare costs of treatment, there is increasing interest in this stringent disease.
Breast cancer is the second leading cause of mortality among women, after the Lung cancer. In United States it is the most common diagnosed form of cancer accounting for the ration of one is to three. As most type of cancers originates from a starting lump, so is the breast cancer. It is the breast tissue where the tumor generates in lobules and ducts that can be classified into invasive and non-invasive stages. A woman living in the US has a 12.3%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer. In 2016, invasive breast cancer will be diagnosed in about 246,660 women and 2,600 men. An additional 61,000 new cases of in situ breast cancer will be diagnosed in women.
US breast cancer market is conquered by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). It was approved in 2012 by the FDA for the treatment of or late stage metastatic HER2-positive breast cancer patients.
Moreover, compounds such as Protein bound paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel and many more generic as well as branded drugs have shown positive results in reducing cancer progression and increasing life expectancy. Recently, branded drug such as Bevacizumab has seen preference among oncologists even though the drug has been advised to be removed from breast cancer indication. The market for metastatic breast cancer for now is highly fragmented between numerous drugs, radiation therapy and alternative therapies such as vitamin therapy, acupuncture, macrobiotic diets, homeopathy and herbal medication. Nano therapy via nano probe technology and various other areas of alternate treatment are under trials to check for their effectiveness in decreasing disease progression and arresting the cancerous cell growth by target specific tumor cell suppression.
Due to extensive research and development in treatment approaches for breast cancer. Breast cancer patients in US have a new surgical option that eliminates exposure to radioactive materials and offers a less invasive, alternative for cancer detection. This strategy has been approved by FDA and will be used to locate early stage tumors. The Sentimag technology platform is a magnetic surgical guidance probe used with nanoparticle tracers and other magnetic devices to more safely and easily determine the spread of cancer.
Historically, Herceptin has ruled the market in US and across the globe but due to its US patent expiration in 2019 its biosimilars might gain the same success stories. The driving forces behind the popularity of this drug are the increasing awareness of breast cancer by the means of several programs and screening aids. Another aspect is the emergence of targeted and combinational therapies. Drugs for the HER 2+ receptors such as Herceptin and Kadcyla can be administered as monotherapy or in the combination for the better survival rates. There are three specific medications that will be pushing this growth forward in breast cancer drug sales. These include; Novartis’ Afinitor, Roche/Genentech’s Perjeta, and trastuzumab-DM1. Afinitor has gained regulatory approval in Europe and the United States to market medication that treats hormone-receptor positive breast cancer, which is expected to raise this company’s peak-year sales past US$ 1 Billion.
Ongoing clinical development of the drug Perjeta is also predicted to help it bring impressive sales through 2021. Targeted therapies are predicted to keep advancing the treatment of breast cancer. Breast cancer drug development is a hive of activity but despite the busy pipeline, forecast has been for the uptake of just three novel agents in this market through 2021. Moreover, two of these agents will penetrate only the HER2-positive market segment, which will continue to be dominated by Roche.
Indeed, Breast cancer is a difficult diagnosis to receive for any women, as these fears up for the low survival rates and every one in eight women develop the breast cancer throughout a lifetime. The healthcare sector and cancer drug market has focused on developing better treatments over the past years and new regimens are on the road to success.
“US Breast Cancer Drug Market Outlook 2022” Report Highlights:
Around the corners of world, cancer has infused itself in every country, region and each habitable land present over earth. Cancer has become one of those nightmares which haunt every individual once in a life time this is because of the increasing incidence rates and no proper care available until now. Given the steady increase in global cancer incidence with its associated morbidity and mortality, together with the spiraling healthcare costs of treatment, there is increasing interest in this stringent disease.
Breast cancer is the second leading cause of mortality among women, after the Lung cancer. In United States it is the most common diagnosed form of cancer accounting for the ration of one is to three. As most type of cancers originates from a starting lump, so is the breast cancer. It is the breast tissue where the tumor generates in lobules and ducts that can be classified into invasive and non-invasive stages. A woman living in the US has a 12.3%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer. In 2016, invasive breast cancer will be diagnosed in about 246,660 women and 2,600 men. An additional 61,000 new cases of in situ breast cancer will be diagnosed in women.
US breast cancer market is conquered by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). It was approved in 2012 by the FDA for the treatment of or late stage metastatic HER2-positive breast cancer patients.
Moreover, compounds such as Protein bound paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel and many more generic as well as branded drugs have shown positive results in reducing cancer progression and increasing life expectancy. Recently, branded drug such as Bevacizumab has seen preference among oncologists even though the drug has been advised to be removed from breast cancer indication. The market for metastatic breast cancer for now is highly fragmented between numerous drugs, radiation therapy and alternative therapies such as vitamin therapy, acupuncture, macrobiotic diets, homeopathy and herbal medication. Nano therapy via nano probe technology and various other areas of alternate treatment are under trials to check for their effectiveness in decreasing disease progression and arresting the cancerous cell growth by target specific tumor cell suppression.
Due to extensive research and development in treatment approaches for breast cancer. Breast cancer patients in US have a new surgical option that eliminates exposure to radioactive materials and offers a less invasive, alternative for cancer detection. This strategy has been approved by FDA and will be used to locate early stage tumors. The Sentimag technology platform is a magnetic surgical guidance probe used with nanoparticle tracers and other magnetic devices to more safely and easily determine the spread of cancer.
Historically, Herceptin has ruled the market in US and across the globe but due to its US patent expiration in 2019 its biosimilars might gain the same success stories. The driving forces behind the popularity of this drug are the increasing awareness of breast cancer by the means of several programs and screening aids. Another aspect is the emergence of targeted and combinational therapies. Drugs for the HER 2+ receptors such as Herceptin and Kadcyla can be administered as monotherapy or in the combination for the better survival rates. There are three specific medications that will be pushing this growth forward in breast cancer drug sales. These include; Novartis’ Afinitor, Roche/Genentech’s Perjeta, and trastuzumab-DM1. Afinitor has gained regulatory approval in Europe and the United States to market medication that treats hormone-receptor positive breast cancer, which is expected to raise this company’s peak-year sales past US$ 1 Billion.
Ongoing clinical development of the drug Perjeta is also predicted to help it bring impressive sales through 2021. Targeted therapies are predicted to keep advancing the treatment of breast cancer. Breast cancer drug development is a hive of activity but despite the busy pipeline, forecast has been for the uptake of just three novel agents in this market through 2021. Moreover, two of these agents will penetrate only the HER2-positive market segment, which will continue to be dominated by Roche.
Indeed, Breast cancer is a difficult diagnosis to receive for any women, as these fears up for the low survival rates and every one in eight women develop the breast cancer throughout a lifetime. The healthcare sector and cancer drug market has focused on developing better treatments over the past years and new regimens are on the road to success.
“US Breast Cancer Drug Market Outlook 2022” Report Highlights:
- US Breast Cancer Tendencies
- US Breast Cancer Drug Market Outline
- US Breast Cancer Drug Market Dynamics
- Breast Cancer Risk Undercurrents
- US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
- US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs
1. US CANCER PREVALENCE RATE
1.1 Overview
1.2 Glimpse of Past Cancer Incidences
1.3 Current Drifts in Cancer Frequencies
1.4 Estimated Future Cancer Occurrences
2. US BREAST CANCER TENDENCIES
2.1 Indication
2.2 Breast Cancer Historical Incidences
2.3 Recent inclinations in Breast Cancer
2.4 Breast Cancer Frequencies over Age & Race
3. BREAST CANCER RISK UNDERCURRENTS
3.1 Hormonal Aspects
3.2 Family History & Genetic Predisposition
3.3 Cumulative Age & Elevated Risk
3.4 Management of Breast Cancer
4. US BREAST CANCER DRUG MARKET OUTLINE
4.1 Topographical Arcade Sales
4.2 HER-2 Positive Drug Market
5. US BREAST CANCER DRUG MARKET DYNAMICS
5.1 Breast Cancer Market Accelerative Parameters
5.2 Breast Cancer Market Challenges
6. US BREAST CANCER DRUG MARKET FUTURE ASPECTS
US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
7. ERIBULIN (HALAVEN)
7.1 Clinical Introduction
7.2 Brand Names
7.3 Recording & Reporting Of Clinical Adverse Events
8. TRASTUZUMAB EMTANSINE (KADCYLA)
8.1 Clinical Introduction
8.2 Brand Names
8.3 Recording & Reporting Of Clinical Adverse Events
9. PALBOCICLIB (IBRANCE)
9.1 Clinical Introduction
9.2 Brand Names
9.3 Recording & Reporting Of Clinical Adverse Events
10. PERTUZUMAB (OMNITARG & PERJETA)
10.1 Clinical Introduction
10.2 Brand Names
10.3 Recording & Reporting Of Clinical Adverse Events
11. GADOBUTROL (GADAVIST, GADOVIST & GADOVIST 1.0)
11.1 Clinical Introduction
11.2 Brand Names
11.3 Recording & Reporting Of Clinical Adverse Events
12. LAPATINIB (TYKERB)
12.1 Clinical Introduction
12.2 Brand Names
12.3 Recording & Reporting Of Clinical Adverse Events
13. TAMOXIFEN ORAL LIQUID (SOLTAMOX)
13.1 Clinical Introduction
13.2 Brand Names
13.3 Recording & Reporting Of Clinical Adverse Events
14. FULVESTRANT (FASLODEX)
14.1 Clinical Introduction
14.2 Brand Names
14.3 Recording & Reporting Of Clinical Adverse Events
15. ANASTROZOLE (ARIMIDEX)
15.1 Clinical Introduction
15.2 Brand Names
15.3 Recording & Reporting Of Clinical Adverse Events
16. IXABEPILONE (IXEMPRA)
16.1 Clinical Introduction
16.2 Brand Names
16.3 Recording & Reporting Of Clinical Adverse Events
17. TOREMIFENE (FARESTON)
17.1 Clinical Introduction
17.2 Brand Names
17.3 Recording & Reporting Of Clinical Adverse Events
18. LETROZOLE (FEMARA)
18.1 Clinical Introduction
18.2 Brand Names
18.3 Recording & Reporting Of Clinical Adverse Events
19. RALOXIFENE (CELVISTA, EVISTA, OPTRUMA & SEVISTA (RALOXIFENE))
19.1 Clinical Introduction
19.2 Brand Names
20. EXEMESTANE (AROMASIN)
20.1 Clinical Introduction
20.2 Brand Names
20.3 Recording & Reporting Of Clinical Adverse Events
21. VITAMIN B12 FLUORESCENT-ANALOGUES (COBALAFLUOR GREEN & COBALAFLUOR RED)
21.1 Clinical Introduction
21.2 Brand Names
22. TRASTUZUMAB COMPANION DIAGNOSTIC (HER2 CISH PHARMDX)
22.1 Clinical Introduction
22.2 Brand Names
23. FLUOXYMESTERONE
23.1 Clinical Introduction
23.2 Recording & Reporting Of Clinical Adverse Events
24. COMPETITIVE LANDSCAPE
24.1 Agilent Technologies
24.2 AstraZeneca
24.3 Bayer HealthCare Pharmaceuticals
24.4 Bristol-Myers Squibb
24.5 Eisai Co Ltd
24.6 Eli Lilly
24.7 Novartis
24.8 Onyx Pharmaceuticals
24.9 Orion
24.10 Perrigo
24.11 Pfizer
24.12 Roche
1.1 Overview
1.2 Glimpse of Past Cancer Incidences
1.3 Current Drifts in Cancer Frequencies
1.4 Estimated Future Cancer Occurrences
2. US BREAST CANCER TENDENCIES
2.1 Indication
2.2 Breast Cancer Historical Incidences
2.3 Recent inclinations in Breast Cancer
2.4 Breast Cancer Frequencies over Age & Race
3. BREAST CANCER RISK UNDERCURRENTS
3.1 Hormonal Aspects
3.2 Family History & Genetic Predisposition
3.3 Cumulative Age & Elevated Risk
3.4 Management of Breast Cancer
4. US BREAST CANCER DRUG MARKET OUTLINE
4.1 Topographical Arcade Sales
4.2 HER-2 Positive Drug Market
5. US BREAST CANCER DRUG MARKET DYNAMICS
5.1 Breast Cancer Market Accelerative Parameters
5.2 Breast Cancer Market Challenges
6. US BREAST CANCER DRUG MARKET FUTURE ASPECTS
US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
7. ERIBULIN (HALAVEN)
7.1 Clinical Introduction
7.2 Brand Names
7.3 Recording & Reporting Of Clinical Adverse Events
8. TRASTUZUMAB EMTANSINE (KADCYLA)
8.1 Clinical Introduction
8.2 Brand Names
8.3 Recording & Reporting Of Clinical Adverse Events
9. PALBOCICLIB (IBRANCE)
9.1 Clinical Introduction
9.2 Brand Names
9.3 Recording & Reporting Of Clinical Adverse Events
10. PERTUZUMAB (OMNITARG & PERJETA)
10.1 Clinical Introduction
10.2 Brand Names
10.3 Recording & Reporting Of Clinical Adverse Events
11. GADOBUTROL (GADAVIST, GADOVIST & GADOVIST 1.0)
11.1 Clinical Introduction
11.2 Brand Names
11.3 Recording & Reporting Of Clinical Adverse Events
12. LAPATINIB (TYKERB)
12.1 Clinical Introduction
12.2 Brand Names
12.3 Recording & Reporting Of Clinical Adverse Events
13. TAMOXIFEN ORAL LIQUID (SOLTAMOX)
13.1 Clinical Introduction
13.2 Brand Names
13.3 Recording & Reporting Of Clinical Adverse Events
14. FULVESTRANT (FASLODEX)
14.1 Clinical Introduction
14.2 Brand Names
14.3 Recording & Reporting Of Clinical Adverse Events
15. ANASTROZOLE (ARIMIDEX)
15.1 Clinical Introduction
15.2 Brand Names
15.3 Recording & Reporting Of Clinical Adverse Events
16. IXABEPILONE (IXEMPRA)
16.1 Clinical Introduction
16.2 Brand Names
16.3 Recording & Reporting Of Clinical Adverse Events
17. TOREMIFENE (FARESTON)
17.1 Clinical Introduction
17.2 Brand Names
17.3 Recording & Reporting Of Clinical Adverse Events
18. LETROZOLE (FEMARA)
18.1 Clinical Introduction
18.2 Brand Names
18.3 Recording & Reporting Of Clinical Adverse Events
19. RALOXIFENE (CELVISTA, EVISTA, OPTRUMA & SEVISTA (RALOXIFENE))
19.1 Clinical Introduction
19.2 Brand Names
20. EXEMESTANE (AROMASIN)
20.1 Clinical Introduction
20.2 Brand Names
20.3 Recording & Reporting Of Clinical Adverse Events
21. VITAMIN B12 FLUORESCENT-ANALOGUES (COBALAFLUOR GREEN & COBALAFLUOR RED)
21.1 Clinical Introduction
21.2 Brand Names
22. TRASTUZUMAB COMPANION DIAGNOSTIC (HER2 CISH PHARMDX)
22.1 Clinical Introduction
22.2 Brand Names
23. FLUOXYMESTERONE
23.1 Clinical Introduction
23.2 Recording & Reporting Of Clinical Adverse Events
24. COMPETITIVE LANDSCAPE
24.1 Agilent Technologies
24.2 AstraZeneca
24.3 Bayer HealthCare Pharmaceuticals
24.4 Bristol-Myers Squibb
24.5 Eisai Co Ltd
24.6 Eli Lilly
24.7 Novartis
24.8 Onyx Pharmaceuticals
24.9 Orion
24.10 Perrigo
24.11 Pfizer
24.12 Roche
LIST OF FIGURES
Figure 1-1: Top Ten Countries in Cancer Incidence Trends
Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012
Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016
Figure 2-1: Relationship between Age & Breast Cancer
Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity
Figure 3-1: Various Risk Factors Associated With Breast Cancer
Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016
Figure 4-2: HER-2 Positive Receptor & Herceptin
Figure 5-1: Accelerative Parameters of Breast Cancer Market
Figure 5-2: Current Challenges in Breast Cancer Therapeutics
Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022
Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022
Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022
Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022
Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022
Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022
Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022
Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022
Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022
Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022
Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022
Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022
Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022
Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022
Figure 18-1: Femara - US Sales (Million US$), 2015-2022
Figure 18-2: Femara - Global Sales (Million US$), 2015-2022
Figure 24-1: Novartis - Clinical Pipeline
Figure 24-2: Roche - Clinical Pipeline
Figure 1-1: Top Ten Countries in Cancer Incidence Trends
Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012
Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016
Figure 2-1: Relationship between Age & Breast Cancer
Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity
Figure 3-1: Various Risk Factors Associated With Breast Cancer
Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016
Figure 4-2: HER-2 Positive Receptor & Herceptin
Figure 5-1: Accelerative Parameters of Breast Cancer Market
Figure 5-2: Current Challenges in Breast Cancer Therapeutics
Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022
Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022
Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022
Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022
Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022
Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022
Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022
Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022
Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022
Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022
Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022
Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022
Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022
Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022
Figure 18-1: Femara - US Sales (Million US$), 2015-2022
Figure 18-2: Femara - Global Sales (Million US$), 2015-2022
Figure 24-1: Novartis - Clinical Pipeline
Figure 24-2: Roche - Clinical Pipeline
LIST OF TABLES
Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016
Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016
Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016
Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016
Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016
Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016
